A patient who underwent adrenalectomy with biopsy showing Histoplasma infection now has intermittent fever and significant weight loss; what is the appropriate treatment and management for disseminated histoplasmosis with adrenal involvement?

Treatment for Disseminated Histoplasmosis with Adrenal Involvement

This patient with biopsy-proven disseminated histoplasmosis and ongoing constitutional symptoms (intermittent fever and significant weight loss) requires immediate induction therapy with liposomal amphotericin B (3 mg/kg daily) for 1-2 weeks, followed by itraconazole (200 mg three times daily for 3 days, then 200 mg twice daily) for at least 12 months. 1

Rationale for Treatment Approach

The presence of intermittent fever and significant weight loss following adrenalectomy indicates progressive disseminated histoplasmosis—a life-threatening condition that is fatal if untreated 1. The IDSA guidelines explicitly classify progressive disseminated infection as having "definite indication with proven efficacy" for antifungal therapy 1.

Induction Therapy: Why Liposomal Amphotericin B

Liposomal amphotericin B is superior to conventional amphotericin B deoxycholate, demonstrating:

• Higher response rate (88% vs 64%)
• Lower mortality (2% vs 13%)

This survival benefit was established in a randomized controlled trial of patients with disseminated histoplasmosis 1. While this trial focused on AIDS patients, the most recent global guideline (2021) recommends lipid formulations of amphotericin B (3-5 mg/kg daily) for 10-14 days in immunocompromised patients with disseminated disease 2.

Alternative options if liposomal amphotericin B is unavailable:

• Amphotericin B lipid complex (5 mg/kg daily) - may be preferred due to lower cost 1
• Amphotericin B deoxycholate (0.7-1.0 mg/kg daily) - only if patient has low nephrotoxicity risk 1

Maintenance Therapy: Itraconazole

After clinical response to amphotericin B (typically 1-2 weeks), transition to itraconazole 200 mg twice daily for at least 12 months 2, 1. The 2021 global guideline emphasizes this duration "pending immune reconstitution" 2.

Critical monitoring requirements:

• Measure itraconazole blood levels after 2 weeks to ensure adequate drug exposure (target trough >1.0 mcg/mL) 1
• Use itraconazole solution on empty stomach when possible (30% higher concentrations than capsules) 1
• If using capsules, take with food or acidic beverage; avoid in patients on proton pump inhibitors or H2 blockers 1
• Monitor hepatic enzymes before starting, then at weeks 1,2,4, and every 3 months 1

Disease Monitoring

Monitor Histoplasma antigen levels (urine or serum) during therapy and for 12 months after completion to detect relapse 1. However, persistent low-level antigenuria alone may not warrant treatment extension if the patient has completed appropriate therapy and shows no clinical evidence of active infection 1.

Assessment of Adrenal Function

Given the adrenal involvement requiring adrenalectomy, assess for adrenal insufficiency immediately:

• Morning cortisol and ACTH levels
• Cosyntropin stimulation test if baseline cortisol is low
• Check electrolytes (hyperkalemia and hyponatremia suggest insufficiency)

Recent case reports demonstrate that adrenal histoplasmosis can cause primary adrenal insufficiency requiring glucocorticoid replacement 3, 4. One case showed improvement in adrenal function over time with antifungal therapy 3, while others maintained normal function despite bilateral involvement 5.

Duration Considerations and Pitfalls

Common pitfall: Inadequate treatment duration. One case report documented persistence of Histoplasma in adrenal tissue 7 years after only 9 months of itraconazole therapy 6. This underscores the importance of:

• Completing the full 12-month course minimum
• Extending therapy if immunosuppression cannot be reversed 1
• Lifelong suppressive therapy (200 mg daily) may be needed in persistently immunosuppressed patients 1

Another critical pitfall: Assuming immunocompetence. While this patient underwent adrenalectomy, evaluate for underlying immunosuppression (HIV, diabetes, chronic corticosteroid use, TNF-α inhibitors) that may require longer therapy 2, 1.

Severity Classification

This patient has moderately severe to severe disease based on:

• Documented dissemination (adrenal involvement)
• Ongoing constitutional symptoms (fever, weight loss)
• Required surgical intervention

This classification mandates amphotericin B induction rather than starting with oral itraconazole alone 1.